Prolonged therapy with imatinib mesylate before surgery for advanced gastrointestinal stromal tumor results of a phase II trial

International Journal of Surgical Oncology

Volumn 2012, Issue , 2012, Pages

  Doyon, C ^a   Sideris L ^a   Leblanc, G ^a   Leclerc, Y E ^a   Boudreau, D ^a   Dube P ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872137802     PISSN: 20901402     EISSN: 20901410     Source Type: Journal    
DOI: 10.1155/2012/761576     Document Type: Article

References (56)

1. Joensuu H., Fletcher C., Dimitrijevic S., Silberman S., Roberts P., Demetri G., Management of malignant gastrointestinal stromal tumours. Lancet Oncology 2002 3 11 655 664 2-s2.0-0036846345 10.1016/S1470-2045(02)00899-9 (Pubitemid 35314908)
2. Kindblom L. G., Remotti H. E., Aldenborg F., Meis-Kindblom J. M., Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. American Journal of Pathology 1998 152 5 1259 1269 2-s2.0-0031947592 (Pubitemid 28221878)
3. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M., Tunio G. M., Matsuzawa Y., Kanakura Y., Shinomura Y., Kitamura Y., Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998 279 5350 577 580 2-s2.0-15644363454 10.1126/science.279.5350.577 (Pubitemid 28067289)
4. Heinrich M. C., Corless C. L., Duensing A., McGreevey L., Chen C. J., Joseph N., Singer S., Griffith D. J., Haley A., Town A., Demetri G. D., Fletcher C. D. M., Fletcher J. A., PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003 299 5607 708 710 2-s2.0-0242670019 10.1126/science.1079666 (Pubitemid 36159485)
5. Hur K., Lee H. J., Woo J. H., Kim J. H., Yang H. K., Gene expression profiling of human gastrointestinal stromal tumors according to its malignant potential. Digestive Diseases and Sciences 2010 55 9 2561 2567 2-s2.0-77956183484 10.1007/s10620-009-1061-4
6. Ylipää A., Hunt K. K., Yang J., Lazar A. J. F., Torres K. E., Lev D. C., Nykter M., Pollock R. E., Trent J., Zhang W., Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer 2011 117 2 380 389 2-s2.0-78650972191 10.1002/cncr.25594
7. Yang J., Du X., Lazar A. J., Pollock R., Hunt K., Chen K., Hao X., Trent J., Zhang W., Genetic aberrations of gastrointestinal stromal tumors. Cancer 2008 113 7 1532 1543 2-s2.0-54049147333 10.1002/cncr.23778
8. DeMatteo R. P., Lewis J. J., Leung D., Mudan S. S., Woodruff J. M., Brennan M. F., Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Annals of Surgery 2000 231 1 51 58 2-s2.0-0033984319 10.1097/00000658-200001000-00008 (Pubitemid 30043939)
9. Plaat B. E. C., Hollema H., Molenaar W. M., Torn Broers G. H., Pijpe J., Mastik M. F., Hoekstra H. J., Van den Berg E., Scheper R. J., Van der Graaf W. T. A., Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. Journal of Clinical Oncology 2000 18 18 3211 3220 2-s2.0-0034666327
10. Novartis Pharmaceuticals Corporation, Gleevec (Imatinib) Prescribing Information 2010 East Hanover, NJ, USA Novartis Pharmaceuticals Corporation
11. Cassier P. A., Blay J. Y., Imatinib mesylate for the treatment of gastrointestinal stromal tumor. Expert Review of Anticancer Therapy 2010 10 5 623 634 2-s2.0-77952522943 10.1586/era.10.33
12. van Oosterom A. T., Judson I. R., Verweij J., Stroobants S., Dumez H., Donato di Paola E., Sciot R., Van Glabbeke M., Dimitrijevic S., Nielsen O. S., Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. European journal of cancer (Oxford, England: 1990) 2002 38 S83 S87 2-s2.0-0036769721
13. Demetri G. D., Von Mehren M., Blanke C. D., Van Den Abbeele A. D., Eisenberg B., Roberts P. J., Heinrich M. C., Tuveson D. A., Singer S., Janicek M., Fletcher J. A., Silverman S. G., Silberman S. L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B. J., Corless C., Fletcher C. D. M., Joensuu H., Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine 2002 347 7 472 480 2-s2.0-0037103424 10.1056/NEJMoa020461 (Pubitemid 34879334)
14. Verweij J., Casali P. G., Zalcberg J., LeCesne A., Reichardt P., Blay J. Y., Issels R., Van Oosterom A., Hogendoorn P. C. W., Van Glabbeke M., Bertulli R., Judson I., Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. The Lancet 2004 364 9440 1127 1134 2-s2.0-20844433223 10.1016/S0140-6736(04)17098-0 (Pubitemid 39296599)
15. Blanke C. D., Demetri G. D., Von Mehren M., Heinrich M. C., Eisenberg B., Fletcher J. A., Corless C. L., Fletcher C. D. M., Roberts P. J., Heinz D., Wehre E., Nikolova Z., Joensuu H., Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Journal of Clinical Oncology 2008 26 4 620 625 2-s2.0-39149123549 10.1200/JCO.2007.13.4403 (Pubitemid 351264357)
16. Zhu J., Yang Y., Zhou L., Jiang M., Hou M., A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. BMC Cancer 2010 10, article no. 199 2-s2.0-77953728645 10.1186/1471-2407-10-199
17. Casali P. G., Jost L., Reichardt P., Schlemmer M., Blay J. Y., Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology 2008 19 supplement 2 ii35 ii38 2-s2.0-45149093253 10.1093/annonc/mdn080
18. Demetri G. D., Von Mehren M., Antonescu C. R., DeMatteo R. P., Ganjoo K. N., Maki R. G., Pisters P. W. T., Raut C. P., Riedel R. F., Schuetze S., Sundar H. M., Trent J. C., Wayne J. D., NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. Journal of the National Comprehensive Cancer Network 2010 8 supplement 2 S1 S44 2-s2.0-77951875556
19. DeMatteo R. P., Ballman K. V., Antonescu C. R., Maki R. G., Pisters P. W., Demetri G. D., Blackstein M. E., Blanke C. D., von Mehren M., Brennan M. F., Patel S., McCarter M. D., Polikoff J. A., Tan B. R., Owzar K., Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. The Lancet 2009 373 9669 1097 1104 2-s2.0-62849096370 10.1016/S0140-6736(09)60500-6
20. Vignot S., Bay J. O., Blay J. Y., Goncalves A., Massard C., Thariat J., Wislez M., Andre: T., American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view. Bulletin Cancer 2011 98 12 1509 1523
21. Gronchi A., Fiore M., Miselli F., Lagonigro M. S., Coco P., Messina A., Pilotti S., Casali P. G., Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Annals of Surgery 2007 245 3 341 346 2-s2.0-34247615184 10.1097/01.sla. 0000242710.36384.1b (Pubitemid 46673127)
22. Mussi C., Ronellenfitsch U., Jakob J., Tamborini E., Reichardt P., Casali P. G., Fiore M., Hohenberger P., Gronchi A., Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Annals of Oncology 2010 21 2 403 408 2-s2.0-77951814300 10.1093/annonc/mdp310
23. Saied G. M., Kensarah A. M., Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients. International Journal of Surgery 2010 8 2 105 108 2-s2.0-77349126631 10.1016/j.ijsu.2009.09.016
24. Von Mehren M., Watson J. C., Perioperative tyrosine kinase inhibitors for GIST: standard-or an idea that needs further investigation? Oncology 2009 23 1 65 66 2-s2.0-61449146247
25. Seshadri R. A., Rajendranath R., Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors. Journal of Cancer Research and Therapeutics 2009 5 4 267 271 2-s2.0-77749254960 10.4103/0973-1482.59905
26. Fiore M., Palassini E., Fumagalli E., Pilotti S., Tamborini E., Stacchiotti S., Pennacchioli E., Casali P. G., Gronchi A., Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). European Journal of Surgical Oncology 2009 35 7 739 745 2-s2.0-67349212626 10.1016/j.ejso.2008.11.005
27. Hohenberger P., Licht T., Dimitrakopoulou-Strauss A., Jakob J., Pink D., Schwarzbach M., Ströbel P., Reichardt P., Wardelmann E., Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology 2009 27 15S
28. Andtbacka R. H. I., Ng C. S., Scaife C. L., Cormier J. N., Hunt K. K., Pisters P. W. T., Pollock R. E., Benjamin R. S., Burgess M. A., Chen L. L., Trent J., Patel S. R., Raymond K., Feig B. W., Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Annals of Surgical Oncology 2007 14 1 14 24 2-s2.0-33845633389 10.1245/s10434-006-9034-8 (Pubitemid 44954266)
29. Raut C. P., Posner M., Desai J., Morgan J. A., George S., Zahrieh D., Fletcher C. D. M., Demetri G. D., Bertagnolli M. M., Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. Journal of Clinical Oncology 2006 24 15 2325 2331 2-s2.0-33744795769 10.1200/JCO.2005.05.3439 (Pubitemid 46630664)
30. Eisenberg B. L., Harris J., Blanke C. D., Demetri G. D., Heinrich M. C., Watson J. C., Hoffman J. P., Okuno S., Kane J. M., Von Mehren M., Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. Journal of Surgical Oncology 2009 99 1 42 47 2-s2.0-58149399145 10.1002/jso.21160
31. McAuliffe J. C., Hunt K. K., Lazar A. J. F., Choi H., Qiao W., Thall P., Pollock R. E., Benjamin R. S., Trent J. C., A randomized, phase II study of preoperative plus postoperative Imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Annals of Surgical Oncology 2009 16 4 910 919 2-s2.0-62149141753 10.1245/s10434-008-0177-7
32. Haller F., Detken S., Schulten H. J., Happel N., Gunawan B., Kuhlgatz J., Füzesi L., Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Annals of Surgical Oncology 2007 14 2 526 532 2-s2.0-33846635001 10.1245/s10434-006-9228-0 (Pubitemid 46175297)
33. Blanke C. D., Rankin C., Demetri G. D., Ryan C. W., Von Mehren M., Benjamin R. S., Raymond A. K., Bramwell V. H. C., Baker L. H., Maki R. G., Tanaka M., Hecht J. R., Heinrich M. C., Fletcher C. D. M., Crowley J. J., Borden E. C., Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of Clinical Oncology 2008 26 4 626 632 2-s2.0-39149127634 10.1200/JCO.2007.13.4452 (Pubitemid 351264358)
34. Verweij J., Casali P. G., Kotasek D., Le Cesne A., Reichard P., Judson I. R., Issels R., van Oosterom A. T., Van Glabbeke M., Blay J. Y., Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analyis of EORTC-ISG-AGITG study 62005. European Journal of Cancer 2007 43 6 974 978 2-s2.0-33947722204 10.1016/j.ejca.2007.01.018 (Pubitemid 46505099)
35. Casali P. G., Verweij J., Kotasek D., Imatinib Mesylate in advanced gastrointestinal stromal tumors (GIST): survival analysis of the intergroup EORTC/ISG/AGITG randomized trial in 946 patients. European Journal of Cancer 2005 3
36. Van Glabbeke M., Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. Journal of Clinical Oncology 2010 28 7 1247 1253 2-s2.0-77949898532 10.1200/JCO.2009.24.2099
37. Cancer therapy evaluation program, Common toxicity criteria manual-Common toxicity criteria. version 2.0. Bethesda, MD, National Cancer Institute, 1999 http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ ctcmanual-v4-10-4-99.pdf
38. Therasse P., Arbuck S. G., Eisenhauer E. A., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000 92 3 205 216 2-s2.0-0034594628
39. Therasse P., Eisenhauer E. A., Verweij J., RECIST revisited: a review of validation studies on tumour assessment. European Journal of Cancer 2006 42 8 1031 1039 2-s2.0-33646401788 10.1016/j.ejca.2006.01.026
40. Choi H., Charnsangavej C., Faria S. D. C., Tamm E. P., Benjamin R. S., Johnson M. M., Macapinlac H. A., Podoloff D. A., CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. American Journal of Roentgenology 2004 183 6 1619 1628 2-s2.0-16644389881 (Pubitemid 44210530)
41. Dindo D., Demartines N., Clavien P. A., Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery 2004 240 2 205 213 2-s2.0-3242713145 10.1097/01.sla.0000133083.54934.ae (Pubitemid 38963009)
42. DeMatteo R. P., Owzar K., Antonescu C. R., Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high-risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. Proceedings of the ASCO Gastrointestinal Cancers Symposium 2008
43. Kaplan E., Meier P., Nonparametric estimator from incomplete observations. Journal of the American Statistical Association 1958 53 457 481
44. Hohenberger P., Eisenberg B., Role of surgery combined with kinase inhibition in the management of gastrointestinal Stromal Tumor (GIST). Annals of Surgical Oncology 2010 17 10 2585 2600 2-s2.0-78049463609 10.1245/s10434-010- 1053-9
45. Gold J. S., DeMatteo R. P., Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance. Annals of Surgical Oncology 2007 14 4 1247 1248 2-s2.0-34047237608 10.1245/s10434-006-9291-6 (Pubitemid 46536824)
46. Gold J. S., DeMatteo R. P., Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Annals of Surgery 2006 244 2 176 184 2-s2.0-33748101399 10.1097/01.sla.0000218080.94145.cf (Pubitemid 44305531)
47. DeMatteo R. P., Maki R. G., Singer S., Gonen M., Brennan M. F., Antonescu C. R., Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Annals of Surgery 2007 245 3 347 352 2-s2.0-34247610583 10.1097/01.sla.0000236630.93587.59 (Pubitemid 46673128)
48. Hohenberger P., Ronellenfitsch U., Oladeji O., Pink D., Ströbel P., Wardelmann E., Reichardt P., Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. British Journal of Surgery 2010 97 12 1854 1859 2-s2.0-78049483265 10.1002/bjs.7222
49. DeMatteo R. P., Gold J. S., Saran L., Gönen M., Kui H. L., Maki R. G., Singer S., Besmer P., Brennan M. F., Antonescu C. R., Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008 112 3 608 615 2-s2.0-38749149936 10.1002/cncr.23199 (Pubitemid 351186201)
50. Braggio E., Braggio D. D. A., Small I. A., Lopes L. F., Valadão M., Gouveia M. E., Moreira A. D. S., Linhares E., Romano S., Bacchi C. E., Renault I. Z., Guimarães D. P., Ferreira C. G., Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors. Anticancer Research 2010 30 6 2407 2414 2-s2.0-77955080475
51. Sanchez Hidalgo J. M., Rufian Peña S., Ciria Bru R., Naranjo Torres A., Muñoz Casares C., Ruiz Rabelo J., Briceño Delgado J., Gastrointestinal stromal tumors (GIST): a prospective evaluation of risk factors and prognostic scores. Journal of Gastrointestinal Cancer 2010 41 1 27 37 2-s2.0-77950189168 10.1007/s12029-009-9102-y
52. Choi H., Charnsangavej C., Faria S. C., Macapinlac H. A., Burgess M. A., Patel S. R., Chen L. L., Podoloff D. A., Benjamin R. S., Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. Journal of Clinical Oncology 2007 25 13 1753 1759 2-s2.0-34249085905 10.1200/JCO.2006.07. 3049 (Pubitemid 46797957)
53. Benjamin R. S., Choi H., Macapinlac H. A., Burgess M. A., Patel S. R., Chen L. L., Podoloff D. A., Charnsangavej C., We should desist using RECIST, at least in GIST. Journal of Clinical Oncology 2007 25 13 1760 1764 2-s2.0-34249030871 10.1200/JCO.2006.07.3411 (Pubitemid 46797958)
54. Phongkitkarun S., Phaisanphrukkun C., Jatchavala J., Sirachainan E., Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate. World Journal of Gastroenterology 2008 14 6 892 898 2-s2.0-40149107435 10.3748/wjg.14.892 (Pubitemid 351325028)
55. Mabille M., Vanel D., Albiter M., Le Cesne A., Bonvalot S., Le Pechoux C., Terrier P., Shapeero L. G., Dromain C., Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!). European Journal of Radiology 2009 69 2 204 208
56. Munchen T. U., Open-label trial of neoadjuvant imatinib mesylate in patients with locally advanced malignant GIST expressing c-kit or platelet-derived growth factor receptor-alpha. NCT00112632 http://www. clinicaltrial.gov/